Notes
Chrysler’s finest? The 300M rates as one of my favourites.
The original cast of Hustle, one of my favourite 2000s series.
Boris Johnson ‘wage growth’ quotation—what matters to a eugenicist isn’t human life, after all. Reposted from Twitter.
For our wonderful niece Esme, a Lego airport set. It is an uncle and aunt’s duty to get decent Lego. My parents got me a great set (Lego 40) when I was six, so getting one at four is a real treat!
Publicity still of Barbara Bach in The Spy Who Loved Me. Reposted from Twitter.
Koala reposted from Twitter.
Photostat of an advertisement in a 1989 issue of the London Review of Books, which my friend Philip’s father lent me. I copied a bunch of pages for some homework. I have since reused a lot of the backs of those pages, but for some reason this 1989 layout intrigued me. It’s very period.
Fiat brochure for Belgium, 1970, with the 128 taking pride of place, and looking far more modern than lesser models in the range.
John Lewis Christmas 2016 parody ad still, reposted from Twitter.
More on the Triumph Mk II at Autocade. Reposted from Car Brochure Addict on Twitter.
The origins of the Lucire trade mark, as told to Amanda’s cousin in an email.
More on the Kenmeri Nissan Skyline at Autocade. Renault Talisman interior and exterior for the facelifted model.
The original 1971 Lamborghini Countach LP500 by Bertone show car. Read more in Lucire.
More on the Audi A2 in Autocade.
I can cite these COVID-19 calculations (infections as a proportion of tests done) with a bit more confidence than the last lot, where many countries’ testing figures had not updated. I see the Kingdom of Saudi Arabia has released its total test numbers now, and they show a pretty good result, too.
Compared to my post of the 7th inst., there are improvements in France, Italy, Switzerland and Germany, while Spain has shown a marked and positive improvement (from 39·58 per cent to 28·25 per cent).
The UK’s delay and its initial reliance on herd immunity, with sycophants up and down the country agreeing, is showing up now as its number grows slightly, from 20·4 per cent on the 7th to 23·88 per cent with the latest data.
The US’s numbers are holding fairly steadily with an increase of 0·8 per cent since the 7th (to 19·78 per cent).
Sweden’s total test figure is one of two inaccurate ones here, having remained unchanged since the last tables, which obviously cannot be right. I estimate they have done around 75,000 tests so far, which would bring the figure to 13·98 per cent, fairly close to the 7th’s, rather than the 19·16 per cent that the Worldometers’ table would have me calculate.
Also statistically similar are Switzerland, South Korea, Australia and Hong Kong, though Hong Kong’s total test figure is also inaccurate (unchanged from the 7th). Singapore is showing a rise with the reports of community transmission. New Zealand is showing a small drop (2·71 to 2·15 per cent), though the percentage change here is less than what the US’s is.
Taiwan continues to see its percentage decline with another 8,000 tests done and only an additional 17 infections since the 7th’s post.
France 132,591 of 333,807 = 39·72%
Spain 169,496 of 600,000 = 28·25%
UK 84,279 of 352,974 = 23·88%
USA 560,433 of 2,833,112 = 19·78%
Italy 156,363 of 1,010,193 = 15·48%
Sweden 10,483 of c. 75,000 = c. 13·98%*
Switzerland 25,449 of 193,800 = 13·13%
Germany 127,854 of 1,317,887 = 9·70%
KSA 4,462 of 115,585 = 3·86%
Singapore 2,532 of 72,680 = 3·48%
New Zealand 1,349 of 62,827 = 2·15%
South Korea 10,537 of 514,621 = 2·05%
Australia 6,359 of 362,136 = 1·76%
Hong Kong 1,010 of 96,709 = 1·04%*
Taiwan 393 of 47,215 = 0·83%
I can be staunch on IP protection in a lot of cases—but in the case of Martin Shkreli of Turing Pharmaceuticals AG hiking the price of an Aids drug from $13·50 to $750 per pill, not so much (for obvious reasons). If you’re in pharmaceuticals, then there has to be some element of wanting to benefit enough of humankind so that they can be, well, alive to better society—or, if you want to be monetarist about it, so they can consume more products and services. Whichever side of politics you’re on, productive people are a good thing for everyone except the arms’ industry. Yet the pharmaceutical industry is the one that’s trying to patent natural ingredients and phenomena—and that’s a step too far. It was something we were taught at law school that could not happen—how can a corporation own nature?—so for the industry to challenge both that jurisprudence smacks of greed. If you didn’t originate it, you shouldn’t be able to own it. Even if it could be protected, nature has been around long enough for that protection to have lapsed. Patenting genes? Please.
Sure, everyone has the right to make a buck from intellectual endeavours, but their track record needs to be a lot cleaner. Why was there so much opposition to TPPA et al? Because there had been far too many cases of corporations taking the piss when it came to basic rights and established laws, and governments haven’t upped their game sufficiently. I love the idea of global trade, the notion “we’re all in this together”, but not at the expense of the welfare of fellow human beings. Simply, I give a shit. Hiking the price of something that costs $13·50 to $750 is laziness at the very least—let’s profit without lifting a finger—and being a douchebag at the worst. And I don’t believe we should reward either of these things.
I have a friend who is against vaccinations—not a position I agree with—but his rationale boils down to his mistrust of Big Pharma. And why should he trust them, with these among their worst cases? (As far as I know, he doesn’t oppose other forms of IP protection.) Somewhere, there’s something that kicks off various positions, and corporate misbehaviour must fuel plenty.
Meanwhile, here’s Martin Shkreli’s point of view, where he doesn’t see his actions as wrongful, as told on Tinder, and as told by Yahoo. His view is that Turing isn’t making a profit and he needs to find ways where it does. He has a duty to his shareholders. It seems incredibly short-term—one would hope that innovation is what turns around a pharmaceuticals’ business—and we come back to the notion that it all feels a bit lazy.
